In this QuickChat, Christina Wichmann, Head of Content at MLO, and Tara Crawford Parks, Director of Translational Research and Development at DNA Genotek, will explore the significance of FDA 510(k) clearance for Colli-Pee™•Dx and how it supports patient-centred STI testing through convenient, private at-home collection of first-void urine specimens. The discussion will cover the science behind standardised sample collection and NucleoPrecision™ technology, as well as the clinical and operational benefits of sample stabilisation, mail-based testing workflows, and integration with validated STI molecular assays.

Sponsored by: